<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704232</url>
  </required_header>
  <id_info>
    <org_study_id>D8000CI-001</org_study_id>
    <nct_id>NCT04704232</nct_id>
  </id_info>
  <brief_title>Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers</brief_title>
  <official_title>Prospective,Double-blind,Randomized,Placebo-controlled Study of Safety,Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlzeCure Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlzeCure Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 b placebo-controlled study in healthy volunteers to study safety, efficacy and&#xD;
      pharmacokinetics of Topical ACD440 on normal skin, skin optimized for penetration and skin&#xD;
      exposed to ultraviolet radiation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory study, no primary or secondary endpoints are being defined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs</measure>
    <time_frame>5 Days</time_frame>
    <description>Not defined as primary as per protocol, but system does not seem to allow omittance of primaries</description>
  </primary_outcome>
  <other_outcome>
    <measure>Laser-evoked potentials as a tool for assessing the efficacy of antinociceptive drugs</measure>
    <time_frame>5 days</time_frame>
    <description>Exploratory efficacy endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual analog scale rating of laser induced pain</measure>
    <time_frame>5 days</time_frame>
    <description>Exploratory efficacy endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentage of subjects with adverse events</measure>
    <time_frame>5 days</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and percentage of subjects with clinically significant changes in 12-lead ECGs, vital signs and laboratory findings</measure>
    <time_frame>5 days</time_frame>
    <description>Safety endpoint</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>ACD440</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are simultaneously exposed to topical administration of ACD440 in a crossover design in separate locations from the placebo exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are simultaneously exposed to topical administration of placebo in a crossover design in separate locations from the ACD440 exposure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACD440</intervention_name>
    <description>Double blind, parallel within subject comparison</description>
    <arm_group_label>ACD440</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLAC</intervention_name>
    <description>Double blind, parallel within subject comparison</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteer&#xD;
&#xD;
          -  Fitzpatrick skin type II or III&#xD;
&#xD;
          -  Women not childbearing potential or highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Clinically significant illness&#xD;
&#xD;
          -  Positive COVID 19 test at screening or COVID 19 infection in the past&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AlzeCure Pharma investigational site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

